CLDX
Price
$40.38
Change
+$0.44 (+1.10%)
Updated
Aug 21 closing price
Capitalization
3.17B
80 days until earnings call
Intraday BUY SELL Signals
HIND
Price
$2.28
Change
+$0.06 (+2.70%)
Updated
Aug 21 closing price
Capitalization
15.79M
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CLDX vs HIND

CLDX vs HIND Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CLDX vs. HIND commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and HIND is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (CLDX: $40.38 vs. HIND: $2.28)
Brand notoriety: CLDX and HIND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 70% vs. HIND: 29%
Market capitalization -- CLDX: $3.17B vs. HIND: $15.79M
CLDX [@Biotechnology] is valued at $3.17B. HIND’s [@Biotechnology] market capitalization is $15.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileHIND’s FA Score has 0 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • HIND’s FA Score: 0 green, 5 red.
According to our system of comparison, HIND is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 3 TA indicator(s) are bullish while HIND’s TA Score has 5 bullish TA indicator(s).

  • CLDX’s TA Score: 3 bullish, 5 bearish.
  • HIND’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, HIND is a better buy in the short-term than CLDX.

Price Growth

CLDX (@Biotechnology) experienced а -3.74% price change this week, while HIND (@Biotechnology) price change was +4.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

CLDX is expected to report earnings on Nov 11, 2026.

HIND is expected to report earnings on Aug 24, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($3.17B) has a higher market cap than HIND($15.8M). CLDX YTD gains are higher at: 48.675 vs. HIND (-33.721). HIND has higher annual earnings (EBITDA): -11.07M vs. CLDX (-305.7M). CLDX has more cash in the bank: 451M vs. HIND (8.8M). HIND has less debt than CLDX: HIND (22.5K) vs CLDX (1.91M). CLDX has higher revenues than HIND: CLDX (865K) vs HIND (153K).
CLDXHINDCLDX / HIND
Capitalization3.17B15.8M20,070%
EBITDA-305.7M-11.07M2,762%
Gain YTD48.675-33.721-144%
P/E RatioN/AN/A-
Revenue865K153K565%
Total Cash451M8.8M5,127%
Total Debt1.91M22.5K8,480%
FUNDAMENTALS RATINGS
CLDX vs HIND: Fundamental Ratings
CLDX
HIND
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
38
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3762
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HIND's Valuation (38) in the null industry is somewhat better than the same rating for CLDX (93) in the Biotechnology industry. This means that HIND’s stock grew somewhat faster than CLDX’s over the last 12 months.

HIND's Profit vs Risk Rating (100) in the null industry is in the same range as CLDX (100) in the Biotechnology industry. This means that HIND’s stock grew similarly to CLDX’s over the last 12 months.

HIND's SMR Rating (99) in the null industry is in the same range as CLDX (99) in the Biotechnology industry. This means that HIND’s stock grew similarly to CLDX’s over the last 12 months.

CLDX's Price Growth Rating (37) in the Biotechnology industry is in the same range as HIND (62) in the null industry. This means that CLDX’s stock grew similarly to HIND’s over the last 12 months.

CLDX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as HIND (100) in the null industry. This means that CLDX’s stock grew similarly to HIND’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXHIND
RSI
ODDS (%)
Bearish Trend 3 days ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 6 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CLDX
Daily Signal:
Gain/Loss:
HIND
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RSST33.690.40
+1.20%
Return Stacked® US Stocks & Mgd Futs ETF
INOV37.990.22
+0.58%
Innovator Intl Dev Pwr Bffr ETF - Nov
SHM47.760.05
+0.10%
Stt Strt® SPDR® Nuveen ICE S/T MuncplETF
DVVY27.34N/A
N/A
Invesco Diversified Dividend Opports ETF
BWG7.74-0.05
-0.64%
BrandywineGLOBAL Global Income Opportunities Fund

HIND and

Correlation & Price change

A.I.dvisor indicates that over the last year, HIND has been loosely correlated with PGEN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HIND jumps, then PGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HIND
1D Price
Change %
HIND100%
+2.70%
PGEN - HIND
49%
Loosely correlated
-3.23%
IMMP - HIND
36%
Loosely correlated
-1.28%
MTNB - HIND
35%
Loosely correlated
+8.93%
CLDX - HIND
32%
Poorly correlated
+1.10%
TNXP - HIND
31%
Poorly correlated
+1.29%
More